1. Benedict RG and Langlykke AF. Antibiotic activity of Bacillus polymyxa. J Bacteriol 1947; 54: 24–25.
2. Stansly PG, Shepherd RG, and White HJ. Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 1947; 81: 43–54 .
3. Hayashi K, Suketa Y, Tsukamoto K, and Suzuki T. Chemical structure of polymyxin D1. Experientia 1966; 22: 354–355.
4. Turgut H. Polimiksinler (Kolistin ve Polimiksin B). Turkiye Klinikleri J Inf Dis Special Topics 2017 ;10: 106-109.
5. Nang SC, Azad MAK, Velkov T, Zhou Q, Li J. Rescuing the Last-Line Polymyxins: Achievements and challenges. Pharmacol Rev 2021; 73: 679–728.
6. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Anti Infect Ther 2015; 13: 1481-1497.
7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333–1341.
8. Kaye SK, Poge MJ, Kaye D. Polymyxins (Polymyxin B and Colistin). In:Bennett JE, Dolin R, Blaser MJ, eds. Principles and Practice of Infectious Diseases. 9th edition Philadelphia, MO: Else-
vier; 2020.
9. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, and Hoogmartens J. Isolation and structural characterization of polymyxin B components. J Chromatogr A 2001b; 912: 369–373.
10. Velkov T, Daib C, Ciccotostoc GD, Cappaic R, Hoyerd D, Lig J. Polymyxins for CNS infections: Pharmacology and neurotoxicity. Pharmacol Ther 2018; 181: 85-90.
11. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811-821.
12. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. Isolation and structural characterization of colistin components. J Antibiot 2001; 54: 595-599.
13. Zgurskaya HI, Löpez CA, and Gnanakaran S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis 2015; 1: 512–522.
14. Zhu Y, Lu J, Han ML, et al. Polymyxins bind to the cell surface of unculturable Acinetobacter baumannii and cause unique dependent resistance. Adv Sci 2015; 7: 2000704.
15. Lin J, Xu C, Fang R, Cao J, Zhang X, Zhao Y, Dong G, Sun Y, and Zhou T. Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China. Antimicrob
Agents Chemother 2019a; 63: 00556-19.
16. Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T.A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of
NADH-quinone oxidoreductase activity. J Antibiot 2013; 67: 147–151.
17. Bhor VM, Thomas CJ, Surolia N, et al. Polymyxin B: an ode to an old antidote for endotoxic shock. Mol Biosyst 2005; 1: 213-222.
18. Guo YB, Chen LP, Cao HW, et al. Polymyxin B antagonizing biological activity of lipopolysaccharide. J Traumatol. 2007; 10: 180-183.
19. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial
surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12: 315-321.
20. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11–25.
21. Jiang X, Yang K, Yuan B, et al. Molecular dynamics simulations informed by membrane lipidomics reveal the structure-interaction relationship of polymyxins with the lipid A-based outer
membrane of Acinetobacter baumannii. J Antimicrob Chemother 2020b; 75: 3534–3543.
22. Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 2016; 48: 583–591.
23. Antoniadou A Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786–790.
24. Zhao M, Wu XJ, Fan YX, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents 2018;
51: 714–720.
25. Jiménez-Mejías ME, Pichardo-Guerrero C, Márquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colis-
tin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:212.
26. Miglis C, Rhodes NJ, Avedissian SN, et al. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018; 62: 01475-17.
27. Manchandani P, Thamlikitkul V, Dubrovskaya Y, et al. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018; 104: 534-553.
28. MacLaren G, Speldman D. https://www.uptodate.com/contents/polymyxins-an-overview.
29. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European
Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of
Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39: 10-39.
30. Solé-Lleonart C, Roberts JA, Chastre J, et al. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect
2016; 22: 359-364.
31. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017;
64: 34-65 .
32. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob
Agents Chemother 2014; 58: 2740-2746.
33. Nation RL, Li J. Polymyxins. In: Cosgrove SE, Crowe SM, Grayson ML eds . Kucers’ The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs.
7th ed. Boca Raton, MO: CRC Press; 2017.
34. Tamma PD, Aitken SA, Bonomo RA, Mathers AJ, Duin D, Clancy CJ. IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections Clinical Infectious Diseases,
ciad428, https://doi.org/10.1093/cid/ciad428
35. Gilbert DN, Chambers HF, Saag MS, et al. The Sanford Guıde To Antimicrobial Therapy 2023; 1-319.
36. Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H & Kuster. SP Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and
MetaAnalysis. Scientific Reports 2019; 9: 15290.
37. Samal S, Mishra SB , Patra SK, et al. Polymyxin monotherapy vs. combination therapy for the treatment of multidrug-resistant ınfections: A Systematic Review and Meta-analysis. Indian
Journal of Critical Care Medicine 2021; 25: 199-206.
38. Bergen PJ, Bulman ZP, Saju S, et al. Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy 2015; 35: 34–42.
39. Zhang H, Zhu Y, Yang N, et al. In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii . Infect Drug
Resist 2021; 14: 4657–4666.
40. Paul M, Daikos GLs , Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an
open-label, randomised controlled trial. Lancet Infect Dis 2018; 18: 391-400.